TG Therapeutics Inc (NASDAQ:TGTX) has earned a consensus recommendation of “Buy” from the nine brokerages that are covering the stock, MarketBeat reports. Three research analysts have rated the stock with a hold recommendation and six have given a buy recommendation to the company. The average 12-month price target among analysts that have covered the stock in the last year is $16.80.
A number of equities analysts have recently weighed in on the company. BidaskClub raised Winmark from a “sell” rating to a “hold” rating in a research report on Tuesday, May 14th. Cantor Fitzgerald assumed coverage on CytomX Therapeutics in a research report on Monday, May 13th. They issued an “overweight” rating and a $21.00 price target for the company. B. Riley reissued a “buy” rating on shares of TG Therapeutics in a research report on Tuesday, June 11th. ValuEngine raised Vanda Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Friday, March 29th. Finally, Zacks Investment Research lowered Zymeworks from a “buy” rating to a “hold” rating in a research report on Saturday, April 6th.
Shares of NASDAQ:TGTX traded up $0.04 during trading on Friday, reaching $8.00. 38,653 shares of the stock were exchanged, compared to its average volume of 1,769,710. The company has a quick ratio of 1.72, a current ratio of 1.72 and a debt-to-equity ratio of 1.89. TG Therapeutics has a 1-year low of $3.32 and a 1-year high of $13.60. The stock has a fifty day moving average price of $7.50.
TG Therapeutics (NASDAQ:TGTX) last issued its earnings results on Friday, May 10th. The biopharmaceutical company reported ($0.43) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.01. TG Therapeutics had a negative return on equity of 309.17% and a negative net margin of 99,471.43%. The company had revenue of $0.04 million for the quarter, compared to analyst estimates of $0.04 million. Equities research analysts anticipate that TG Therapeutics will post -1.58 earnings per share for the current fiscal year.
In other TG Therapeutics news, CEO Michael S. Weiss acquired 50,000 shares of TG Therapeutics stock in a transaction on Wednesday, June 26th. The stock was purchased at an average price of $7.04 per share, for a total transaction of $352,000.00. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CFO Sean A. Power sold 17,654 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $8.47, for a total value of $149,529.38. The disclosure for this sale can be found here. Corporate insiders own 14.20% of the company’s stock.
A number of large investors have recently made changes to their positions in the business. venBio Select Advisor LLC grew its stake in TG Therapeutics by 13.1% in the 4th quarter. venBio Select Advisor LLC now owns 4,750,000 shares of the biopharmaceutical company’s stock valued at $19,475,000 after purchasing an additional 549,969 shares during the period. BlackRock Inc. grew its stake in TG Therapeutics by 2.2% in the 4th quarter. BlackRock Inc. now owns 4,519,331 shares of the biopharmaceutical company’s stock valued at $18,529,000 after purchasing an additional 98,479 shares during the period. Great Point Partners LLC grew its stake in TG Therapeutics by 53.8% in the 4th quarter. Great Point Partners LLC now owns 3,000,000 shares of the biopharmaceutical company’s stock valued at $12,300,000 after purchasing an additional 1,050,000 shares during the period. Deutsche Bank AG grew its stake in TG Therapeutics by 72.2% in the 4th quarter. Deutsche Bank AG now owns 824,164 shares of the biopharmaceutical company’s stock valued at $3,378,000 after purchasing an additional 345,477 shares during the period. Finally, Two Sigma Investments LP grew its stake in TG Therapeutics by 312.9% in the 4th quarter. Two Sigma Investments LP now owns 769,011 shares of the biopharmaceutical company’s stock valued at $3,153,000 after purchasing an additional 582,771 shares during the period. Hedge funds and other institutional investors own 54.60% of the company’s stock.
TG Therapeutics Company Profile
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Read More: How Do You Calculate Return on Equity (ROE)?
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.